Physician profile
Erin Deegan
NPI 1033344239
$2,866.52
in general payments reported to CMS, 2019-2025
33 companies · $1,252 in 2025
The $1,252 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $434 · 2020: $291 · 2021: $453 · 2022: $256 · 2024: $180 · 2025: $1,252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,286 · Education: $146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,286.14 |
| Education | $145.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $365.79 | 2021-2025 | |
| Amneal Pharmaceuticals LLC | $261.71 | 2021-2025 | Crexont, Rytary |
| Allergan, INC. | $244.74 | 2019-2021 | |
| Amgen INC. | $230.87 | 2019-2025 | Uplizna |
| Neurocrine Biosciences, INC. | $230.02 | 2024-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $217.39 | 2019-2025 | Austedo Xr |
| Csl Behring | $144.61 | 2020-2022 | |
| Lundbeck LLC | $110.66 | 2021-2025 | Rexulti |
| Lilly USA, LLC | $102.96 | 2019-2022 | |
| Mdd US Operations, LLC | $78.76 | 2019-2025 | |
| Revance Therapeutics, INC. | $70.42 | 2024 | Daxxify |
| Genzyme Corporation | $69.26 | 2019-2025 | |
| Genentech USA, INC. | $66.52 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $59.27 | 2019-2021 | |
| Merz Pharmaceuticals, LLC | $57.43 | 2025 | Xeomin, Inbrija |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $56.09 | 2025 | Nuplazid |
| Biohaven Pharmaceuticals, INC. | $51.31 | 2021 | |
| Adamas Pharmaceuticals, INC. | $50.32 | 2019-2020 | |
| Sk Life Science, INC. | $47.14 | 2021-2025 | |
| Biogen, INC. | $41.16 | 2021-2025 | Vumerity |
| Grifols USA, LLC | $38.52 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $35.93 | 2025 | Acthar |
| Medtronic, INC. | $34.49 | 2025 | Intellis Adaptivestim |
| Boston Scientific Corporation | $28.43 | 2022 | |
| Neurelis, INC. | $26.93 | 2025 | Valtoco |
| Jazz Pharmaceuticals INC. | $24.70 | 2025 | |
| Ge Healthcare | $21.24 | 2019 | |
| Argenx US, INC. | $19.90 | 2025 | Vyvgart |
| Avion Pharmaceuticals | $18.79 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $17.38 | 2025 | Dysport |
| Axsome Therapeutics, INC. | $15.75 | 2025 | Auvelity |
| Pfizer INC. | $14.57 | 2025 | |
| Eisai INC. | $13.46 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Deegan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.